Rocket Pharmaceuticals Receives Buy Rating Due to Promising RP-A501 Data and FDA Alignment for Danon Disease Treatment
Analyst Cory Jubinville, PhD of LifeSci Capital maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report), retaining the price ...
TD Cowen Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)
TD Cowen analyst Tyler Van Buren maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The company’s shares closed ...
Lockheed Martin Just Lost a Multibillion-Dollar Deal -- but All Hope Is Not Lost
Lockheed Martin Just Lost a Multibillion-Dollar Deal -- but All Hope Is Not Lost was originally published by The Motley Fool ...
datanami.com4h
Tips on Building a Winning Data and AI Strategy from JPMC
With $274 billion in revenue last year and $3.3 trillion in assets under management, JPMorgan Chase has more resources than ...
Biden ATACMS Decision Spurs Russian Threats, Hope and Derision Elsewhere
President-elect Donald Trump’s National Security Advisor nominee criticized the Biden administration for easing restrictions ...